Y.D. More Investments Ltd Has $5.33 Million Stock Holdings in Cellebrite DI Ltd. $CLBT

Y.D. More Investments Ltd lessened its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 34.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 287,584 shares of the company’s stock after selling 153,995 shares during the period. Y.D. More Investments Ltd owned 0.12% of Cellebrite DI worth $5,329,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of CLBT. Financial Management Professionals Inc. acquired a new position in shares of Cellebrite DI in the third quarter worth approximately $28,000. CWM LLC raised its stake in Cellebrite DI by 85.7% during the third quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after buying an additional 720 shares during the last quarter. Toth Financial Advisory Corp acquired a new position in Cellebrite DI in the third quarter valued at $38,000. PNC Financial Services Group Inc. boosted its position in Cellebrite DI by 1,998.0% during the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock valued at $34,000 after acquiring an additional 1,998 shares during the last quarter. Finally, Pacer Advisors Inc. grew its holdings in Cellebrite DI by 523.4% during the 3rd quarter. Pacer Advisors Inc. now owns 2,743 shares of the company’s stock worth $51,000 after acquiring an additional 2,303 shares during the period. 45.88% of the stock is owned by institutional investors.

Analyst Ratings Changes

CLBT has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Bank of America boosted their target price on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. JPMorgan Chase & Co. increased their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Needham & Company LLC reduced their target price on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Finally, Lake Street Capital upped their price target on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Cellebrite DI Stock Up 1.5%

CLBT stock traded up $0.20 during mid-day trading on Friday, reaching $13.98. 16,474 shares of the company traded hands, compared to its average volume of 1,750,231. The stock has a market cap of $3.35 billion, a price-to-earnings ratio of 44.24, a P/E/G ratio of 2.15 and a beta of 1.28. Cellebrite DI Ltd. has a fifty-two week low of $13.10 and a fifty-two week high of $20.86. The firm’s 50 day moving average price is $16.71 and its 200 day moving average price is $16.99.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.14. The company had revenue of $128.82 million for the quarter, compared to analyst estimates of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The company’s revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter last year, the company earned $0.10 earnings per share. On average, analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.